22 October 2026 | Thursday | Company results Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the third quarter of fiscal year 2026. [Consolidated earnings for CDMO business, KRW billion] Business Updates and 2026 Outlook Samsung Biologics updated…
John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through commercial manufacturing, and choosing a long-term fill-finish partner Inside Kindeva’s New Sterile Fill-Finish Facility John Wichelt discusses Kindeva’s Bridgeton facility, supporting injectable programs from clinical development through…
The company was selected for the country’s Industrialization and Health Capacities 2030 program earlier this year. French biotechnology supplier VERDOT announced today that it has opened a facility in Saint-Beauzire, France, within the Biopôle Clermont-Limagne life sciences technology park. The new…
Seoul High Court has extended its injunction from three to nine manufacturing stages at Songdo, days before a planned three-week strike, with the CDMO stressing supply continuity for its global clients Samsung Biologics has won an appeals court ruling banning…
19 October 2026 | Monday | News Following an evaluation of factors including government policies, market conditions, workforce recruitment and logistics, Jyong Biotech has submitted a facility and operations plan to local government authorities in the State of Texas and is preparing to commence…
Rising biologic demand strains biomanufacturing capacity, but this BPI report reveals process intensification technologies closing the gap. Bringing Bioproduction Facilities into an Intensified Future Sponsored by Rezon Bio, Sartorius, Tosoh Bioscience, Evotec, Vaisala This October 2026 BPI Featured Report tackles a…
BioPharma APAC - South Koreaâs GCCL and LabConnect Partner to Strengthen Global Clinical Trial Operations Across APAC and North America 14 October 2026 | Wednesday | News GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today…
BioPharma APAC - LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity 13 October 2026 | Tuesday | News LOTTE Biologics and Alvotech Partnership Signing Ceremony Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New…
BioPharma APAC - Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand Identity 07 October 2026 | Wednesday | News - Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network…
Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network. Alvotech has agreed to a long-term manufacturing partnership with LOTTE Biologics, under which the contract development and manufacturing organization (CDMO) will produce…
Contract development and manufacturing from the trade press: CDMOs such as Lonza, Samsung Biologics, WuXi Biologics and Fujifilm, their sites, capacity, deals and the BIOSECURE fallout.
An article joins this feed when it matches these terms. Each one is also a search of its own.